These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 26177791

  • 1. Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.
    Natsag J, Kendall MA, Sellmeyer DE, McComsey GA, Brown TT.
    HIV Med; 2016 Mar; 17(3):196-205. PubMed ID: 26177791
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, Mizunuma H, Inoue T, Saito H, Nakamura T, e-ADVANCED Study Group.
    Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
    [Abstract] [Full Text] [Related]

  • 3. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 4. Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
    Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, Peng YD, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L.
    Medicine (Baltimore); 2018 Aug; 97(31):e11694. PubMed ID: 30075569
    [Abstract] [Full Text] [Related]

  • 5. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
    Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.
    Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
    [Abstract] [Full Text] [Related]

  • 6. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Reginster JY, Pong A, Rosenberg E, Santora A, FOCUS-D Investigators.
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [Abstract] [Full Text] [Related]

  • 7. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [Abstract] [Full Text] [Related]

  • 8. No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year.
    Jorde R, Sneve M, Torjesen PA, Figenschau Y, Hansen JB, Grimnes G.
    Nutr J; 2010 Jan 07; 9():1. PubMed ID: 20056003
    [Abstract] [Full Text] [Related]

  • 9. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006 Jan 07; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 10. Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats.
    Wang Y, Huang P, Tang PF, Chan KM, Li G.
    J Orthop Surg Res; 2011 Jul 13; 6():34. PubMed ID: 21752290
    [Abstract] [Full Text] [Related]

  • 11. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
    Zheng H, Wang C, He JW, Fu WZ, Zhang ZL.
    Pharmacogenet Genomics; 2016 Jan 13; 26(1):12-9. PubMed ID: 26426211
    [Abstract] [Full Text] [Related]

  • 12. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar 13; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May 13; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 14. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 15. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 30; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 16. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.
    Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, Hoffmann ME, Tebas P.
    J Acquir Immune Defic Syndr; 2005 Apr 01; 38(4):426-31. PubMed ID: 15764959
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct 01; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 18. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
    Binkley N, Ringe JD, Reed JI, Ljunggren O, Holick MF, Minne HW, Liu M, Lamotta A, West JA, Santora AC.
    Bone; 2009 Apr 01; 44(4):639-47. PubMed ID: 19185560
    [Abstract] [Full Text] [Related]

  • 19. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
    Rozenberg S, Lanoy E, Bentata M, Viard JP, Valantin MA, Missy P, Darasteanu I, Roux C, Kolta S, Costagliola D, ANRS 120 Fosivir Study Group.
    AIDS Res Hum Retroviruses; 2012 Sep 01; 28(9):972-80. PubMed ID: 22353022
    [Abstract] [Full Text] [Related]

  • 20. Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women.
    Shapses SA, Kendler DL, Robson R, Hansen KE, Sherrell RM, Field MP, Woolf E, Berd Y, Mantz AM, Santora AC.
    J Bone Miner Res; 2011 Aug 01; 26(8):1836-44. PubMed ID: 21448918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.